|
Parameter
|
Ibrutinib
|
Acalabrutinib
|
Zanubrutinib
|
Orelabrutinib
|
LOXO-305
|
|---|
|
Patients (n)
|
111
|
124
|
86
|
97 (106)
|
38
|
|
Age (years)
|
68
|
68
|
60.5
|
NA
|
69
|
|
Prior SCT
|
11%
|
18%
|
3.5%
|
NA
|
25%
|
|
Prior BTKi
|
NA
|
NA
|
NA
|
NA
|
93%
|
|
ORR
|
67%
|
80%
|
84%
|
87.9%
|
52%
|
|
CR
|
23%
|
40%
|
67.5%
|
27.4%
|
25%
|
|
DOR (months)
|
17.5
|
25.7
|
19.5
|
NR
|
NR
|
|
Median PFS (months)
|
13.0
|
NR
|
22.1
|
NR
|
NR
|
|
Median OS %, months
|
47%, 24
|
87%, 12
|
84%, 12
|
88.7%, 12
|
NR
|
|
New A Fib
|
11%
|
0%
|
0%
|
0%
|
< 1%
|
|
Neutropenia, severe
|
17%
|
11%
|
19.8%
|
NA
|
NA
|
|
Pneumonia, severe
|
6%
|
6%
|
9.3%
|
NA
|
NA
|
|
Bleeding, severe
|
6%
|
2.4%
|
2.3%
|
0
|
< 1%
|
|
Reference
|
[40]
|
[39]
|
[38]
|
[37]
|
[41]
|
- A fib, atrial fibrillation; BTKi, Bruton tyrosine kinase inhibitor; NA, not applicable; NR, not reached
